^
    3years
    [VIRTUAL] SCR6106, an oral and brain penetrant SERD demonstrated anti-tumor activities in vitro and in vivo (AACR 2021)
    Fulvestrant, a selective estrogen receptor degrader (SERD) is approved to treat HR+ metastatic breast cancer in patients with disease progression after endocrine therapy. In conclusion, SCR6106 is a novel, potent and oral SERD, which demonstrated anti-tumor activities in vitro and in vivo. It showed high potential ability to cross the blood-brain barrier, and could be used to treat HR+ patients with brain metastasis.
    Preclinical
    |
    ER (Estrogen receptor)
    |
    HR positive
    |
    fulvestrant • SCR6106